NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
Bristol-Myers Squibb
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Eli Lilly and Company
Celldex Therapeutics
Sunnybrook Health Sciences Centre